Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKLIEF vs AVAGE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AKLIEF (trifarotene) is a selective retinoic acid receptor (RAR) gamma agonist. It modulates gene expression by binding to RAR-gamma, leading to normalization of follicular keratinization, reduced comedogenesis, and anti-inflammatory effects.
Avage (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity and modulates gene expression, leading to reduced keratinocyte proliferation, differentiation, and inflammation.
FDA-approved for the topical treatment of acne vulgaris in patients 9 years of age and older
FDA-approved for the topical treatment of stable plaque psoriasis (up to 20% body surface area),FDA-approved for the topical treatment of mild to moderate acne vulgaris,Off-label: treatment of photoaging, facial wrinkles, and certain hyperpigmentation disorders
Apply a thin layer to affected areas once daily in the evening, avoiding eyes, lips, and mucous membranes.
Applied topically as a cream 0.05% to affected areas once daily at bedtime.
Terminal elimination half-life: ~29 hours after topical application; supports once-daily dosing.
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Trifarotene is metabolized primarily via CYP2D6 and to a lesser extent via CYP3A4. It undergoes extensive first-pass metabolism with low systemic exposure after topical application.
Tazarotene is rapidly metabolized via ester hydrolysis to its active metabolite, tazarotenic acid. Tazarotenic acid is further metabolized via oxidation and conjugation (glucuronidation). The enzymes involved include esterases and possibly CYP450 isoforms; specific CYP450 enzymes are not well characterized.
Fecal: ~70% as unchanged drug; Renal: <1% as metabolites.
Primarily renal excretion (70-80% as unchanged drug) with 10-20% biliary/fecal elimination.
>99% bound to plasma proteins (primarily albumin and lipoproteins).
Approximately 90% bound to albumin and alpha-1-acid glycoprotein.
Not determined for topical route; systemic absorption minimal with Vd not clinically relevant.
0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid.
Topical: ~1% systemic absorption; oral: not applicable.
Oral: 60-70% due to first-pass metabolism; Intravenous: 100%.
No dose adjustment required in renal impairment. Not studied in severe renal impairment.
No specific dose adjustment required for renal impairment.
No dose adjustment required in mild to moderate hepatic impairment (Child-Pugh A, B). Not studied in severe hepatic impairment (Child-Pugh C).
No specific dose adjustment required for hepatic impairment.
Approved for acne vulgaris in patients aged 12 years and older: apply a thin layer to affected areas once daily in the evening.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No specific dose adjustment required; clinical studies did not include sufficient geriatric patients to determine differential response.
No specific dose adjustment required; however, use with caution due to potential increased sensitivity and skin fragility in elderly patients.
None.
Avage is contraindicated in women who are or may become pregnant. Tazarotene is a teratogen, and fetal harm can occur when administered to a pregnant woman. If the drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
Local skin reactions (erythema, scaling, dryness, stinging/burning) may occur; reduce frequency or discontinue if severe.,Avoid excessive exposure to sunlight or UV light; use sunscreens and protective clothing.,Avoid contact with eyes, mouth, angles of the nose, and mucous membranes.,Pregnancy: Limited data; no known risk of major malformations based on animal studies, but use only if clearly needed.
Avoid contact with eyes, mouth, and mucous membranes,Not for use on eczematous or sunburned skin,May cause severe local skin reactions (e.g., redness, peeling, burning, stinging),Photosensitivity: patients should avoid or minimize exposure to sunlight and artificial UV sources,Concomitant use with other photosensitizing agents should be approached with caution
Hypersensitivity to trifarotene or any component of the formulation
Pregnancy (FDA Pregnancy Category X),Women of childbearing potential unless using effective contraception and have a negative pregnancy test within 2 weeks prior to therapy,Hypersensitivity to tazarotene or any component of the formulation
No significant food interactions reported. Avoid excessive alcohol consumption as it may exacerbate skin dryness and irritation. No specific dietary restrictions.
AVAGE should be taken with a meal containing fat (e.g., whole milk, peanut butter) to enhance absorption. Avoid excessive vitamin A supplements as they may add to toxic effects. Grapefruit juice may increase isotretinoin levels; consider avoidance.
Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show embryofetal toxicity at high doses. Risk cannot be ruled out. Second and third trimesters: Limited data; avoid unless benefit outweighs risk.
FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects (cleft lip/palate), cardiovascular abnormalities, and neural tube defects. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and premature closure of the ductus arteriosus. Avoid use throughout pregnancy.
No data on excretion in human milk; M/P ratio unknown. Caution advised due to potential for serious adverse reactions in nursing infants.
Contraindicated in breastfeeding. Excreted into human milk; M/P ratio not established. Risk of serious adverse effects in nursing infant, including keratoderma-like skin changes and potential for growth impairment.
No specific dose adjustments recommended; pharmacokinetic changes in pregnancy unknown. Use lowest effective dose if necessary.
No dose adjustment applicable; drug is absolutely contraindicated in pregnancy due to teratogenicity. No data on pharmacokinetic changes; theoretical increased clearance due to expanded plasma volume may occur but is clinically irrelevant given contraindication.
AKLIEF (trifarotene) is a fourth-generation retinoid selective for RAR-γ receptors, minimizing irritation compared to tretinoin. Use pea-sized amount for entire face; avoid excessive application. Initiate every other night to improve tolerability. Concomitant use of benzoyl peroxide or salicylic acid may increase dryness; advise non-comedogenic moisturizers. Contraindicated in pregnancy (Category X); rule out pregnancy before starting.
AVAGE (isotretinoin) is highly teratogenic; confirm negative pregnancy test within 5 days before starting therapy and monthly thereafter. Monitor triglycerides, liver function, and CBC at baseline and monthly. Avoid blood donation during treatment and for 1 month after discontinuation. Use with caution in patients with depression; monitor for mood changes. Administer with food to increase absorption.
Apply a thin layer once daily at night to clean, dry skin.,Avoid sun exposure and use broad-spectrum SPF 30+ sunscreen daily.,May cause initial redness, peeling, and dryness; use moisturizer.,Do not use if pregnant or planning pregnancy; use effective contraception.,Do not apply to cuts, abrasions, or eczematous skin.,Avoid waxing or laser hair removal during treatment.,Therapeutic effect may take 8-12 weeks.,Keep out of reach of children and away from eyes, mouth, and mucous membranes.
AVAGE can cause severe birth defects; females must use two effective forms of contraception and have monthly pregnancy tests.,Do not donate blood while taking AVAGE and for 1 month after stopping.,Avoid exposure to sunlight or tanning beds; use sunscreen and protective clothing.,Report any signs of depression, mood changes, or thoughts of self-harm immediately.,Take each dose with a full meal to ensure proper absorption.,May cause dry skin, lips, eyes; use moisturizers and artificial tears as needed.,Avoid waxing or laser treatments during therapy and for 6 months after.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKLIEF vs AVAGE, answered by our medical review team.
AKLIEF is a Topical Retinoid that works by AKLIEF (trifarotene) is a selective retinoic acid receptor (RAR) gamma agonist. It modulates gene expression by binding to RAR-gamma, leading to normalization of follicular keratinization, reduced comedogenesis, and anti-inflammatory effects.. AVAGE is a Topical Retinoid that works by Avage (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity and modulates gene expression, leading to reduced keratinocyte proliferation, differentiation, and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKLIEF and AVAGE depend on the specific clinical indication. These are both Topical Retinoid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKLIEF is: Apply a thin layer to affected areas once daily in the evening, avoiding eyes, lips, and mucous membranes.. The standard adult dose of AVAGE is: Applied topically as a cream 0.05% to affected areas once daily at bedtime.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKLIEF and AVAGE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKLIEF is classified as Category C. Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show embryofetal toxicity at high doses. Risk cannot be ruled out. Second and third trimesters:. AVAGE is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects (cleft lip/palate), cardiovascular abnormalities, and neural t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.